Biodel Issues Correction on Earlier Release Related to BIOD-238, BIOD-250
In a release issued earlier today by Biodel Inc. (Nasdaq: BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows:
Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires. 100 mm is defined as the worst possible discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS score was numerically lower, but not significantly different for BIOD-250 compared to Humalog^® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and Humalog^®, respectively; p=NS). The VAS score for BIOD-238 was significantly higher than that associated with Humalog^® (mean VAS score of 24.2 mm, p=0.029 vs. Humalog^®).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.